A Double-Blind, Placebo-Comparison Study to Evaluate the Efficacy and Safety of ACTIQ® (Oral Transmucosal Fentanyl Citrate [OTFC®]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain
The primary objective of the study is to evaluate the efficacy of ACTIQ treatment for the
management of breakthrough pain (BTP) compared to placebo treatment in children with pain
who are receiving around-the-clock (ATC) opioid therapy and who require additional therapy
for BTP episodes. This will be determined by the analysis of the pain intensity (PI),
measured by the Faces Pain Scale–Revised (FPS–R) administered 15 minutes after the start of
each unit of study drug with an optimal ACTIQ dosage.
The secondary objectives are:
- to evaluate the characteristics of BTP in children with pain, including their response
to treatment
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these
children with regard to time to adequate analgesia by utilizing a stop watch to measure
the time for each unit of study drug in the double blind phase
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these
children by assessing the occurrence of inadequate analgesia as assessed by the use of
rescue medication
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these
children by assessing the numbers of patients who withdraw from the study because of
inadequate analgesia
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these
children by assessing the duration of analgesic effect by using the FPS–R administered
at approximately 30, 45, and 60 minutes after the start of each unit of study drug
after an optimal dosage is obtained
- to determine the distribution of optimal doses of ACTIQ treatment for these children by
age group (3 to under 6 years, 6 to under 11 years, and 11 to under 16 years)
- to establish a safe and effective titration scheme for ACTIQ in these children during
the open label phase
- to evaluate the safety of ACTIQ treatment for these children through the assessment of
adverse events, clinical laboratory assessments (serum chemistry and hematology), vital
sign measurements (including blood pressure, heart rate, and respiration rate),
hemoglobin-oxygen saturation level (SpO2, measured via pulse oximetry),
electrocardiograms (ECGs), physical examinations, and level of sedation (measured by
the University of Michigan Sedation Scale [UMSS])
- to characterize the pharmacokinetics profile of ACTIQ (fentanyl citrate) in these
children
- to investigate the exposure and efficacy relationship between plasma concentration of
fentanyl and clinical measures of analgesia
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Pain intensity differences as measured by the FPS-R
John Messina, Pharm D
Study Director
Cephalon
United States: Food and Drug Administration
C8278b/202/BP/US-CA
NCT00236041
April 2004
August 2006
Name | Location |
---|---|
Cancer Institute of New Jersey | New Brunswick, New Jersey 08901 |
Hackensack University Medical Center | Hackensack, New Jersey 07601 |
Children's National Medical Center | Washington, District of Columbia 20010-2970 |
Cardinal Glennon Children's Hospital | Saint Louis, Missouri 63104 |
St. Christopher's Hospital for Children | Philadelphia, Pennsylvania 19134-1095 |
Akron Children's Hospital | Akron, Ohio 44308-1062 |
Tod Children's Hospital | Youngstown, Ohio 44501 |
St. Joseph's Children's Hospital | Tampa, Florida 33677-4227 |
Methodist Hospital | Houston, Texas 77030 |
SUNY Upstate Medical University | Syracuse, New York 13210 |
Children's Memorial Hospital | Chicago, Illinois 60614 |
University of New Mexico | Albuquerque, New Mexico 87131 |
Sacred Heart Medical Center | Spokane, Washington 99204 |
West Virginia University | Morgantown, West Virginia 26506 |
Children's Hospital of Arkansas | Little Rock, Arkansas 72202 |
UCLA Pediatric Pain Program | Los Angeles, California 90095 |
Childrens Hospital of Orange | Orange, California 92868 |
Lucille Packard Childrens Hospital | Palo Alto, California 94304 |
Connecticut Childrens Medical Center | Hartford, Connecticut 06106 |
Nemours Childrens Clinic | Jacksonville, Florida 32207 |
Scottish Rite Children's Medical Center | Atlanta, Georgia 30342 |
Kapi'olani Medical Center | Honolulu, Hawaii 96826 |
Children's Memorial Center | Chicago, Illinois 60614 |
University Hospitals of Iowa | Iowa City, Iowa 52242 |
Children's Hospital at Montefiore | Bronx, New York 10467 |
Duke University Hospital | Durham, North Carolina 27710 |
Milton S Hershey Medical Center | Hershey, Pennsylvania 17033 |
Vanderbilt University Medical | Nashville, Tennessee 37232 |
Children's Cancer and Blood Disorders Center | San Antonio, Texas 78207 |
Childrens Hospital of Wisconsin | Milwaukee, Wisconsin 53201 |